标题:Ibrutinib in B-cell lymphoma: Single fighter might be enough?
作者:Xue C.; Wang X.; Zhang L.; Qu Q.; Zhang Q.; Jiang Y.
作者机构:[Xue, C] Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, China;[ Wang, X] Dep 更多
通讯作者:Jiang, Y(yujiejiang05@126.com)
通讯作者地址:[Jiang, Y] Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, China;
来源:Cancer Cell International
出版年:2020
卷:20
期:1
DOI:10.1186/s12935-020-01518-y
关键词:B cell receptor (BCR) signaling pathway; B-cell lymphoma; Bruton's tyrosine kinase (BTK); Ibrutinib; Monotherapy
摘要:Background: In recent years, the B cell receptor (BCR) signaling pathway has become a "hot point"because it plays a critical role in B-cell proliferation and function. Bruton's tyrosine kinase (BTK) is overexpressed in many subtypes of B-cell lymphoma as a downstream kinase in the BCR signaling pathway. Ibrutinib, the first generation of BTK inhibitor, has shown excellent antitumor activity in both indolent and aggressive B-cell lymphoma. Main body: Ibrutinib monotherapy has been confirmed to be effective with a high response rate (RR) and well-tolerated in many B-cell lymphoma subgroups. To achieve much deeper and faster remission, combination strategies contained ibrutinib were conducted to evaluate their synergistic anti-tumor effect. Conclusions: For patients with indolent B-cell lymphoma, most of them respond well with ibrutinib monotherapy. Combination strategies contained ibrutinib might be a better choice to achieve deeper and faster remission in the treatment of aggressive subtypes of B-cell lymphoma. Further investigations on the long-term efficacy and safety of the ibrutinib will provide novel strategies for individualized treatment of B-cell lymphoma. © 2020 The Author(s).
收录类别:SCOPUS
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092246939&doi=10.1186%2fs12935-020-01518-y&partnerID=40&md5=370d37b01066d256ff01e41438f27a3c
TOP